Utah People's Post

The Latest News from the Beehive State

Sunday, March 7, 2021
Log in
  • National News
    • Female Caseworker Killed & Doctor Shot in Philadelphia
  • State News
    • Car Chase Leads to Drug Arrest
  • Tech & Science
  • Health
    • How to Prepare For Ticks Season
    • Magical Weight Loss Bean Scam
  • Sports
  • Business
You are here: Home / Health / Novartis’ Signifor LAR therapy highly effective in acromegaly patients

Novartis’ Signifor LAR therapy highly effective in acromegaly patients

May 5, 2014 Posted by Contributor

Swiss drug maker Novartis on Monday presented the final-stage trial of Signifor long-acting release (LAR) therapy and expressed confidence that it can do wonders in treating patients with the endocrine disorder acromegaly than existing therapies.

The clinical trial was presented at the 16th European Congress of Endocrinology3.

The study, conducted by Novartis, showed that patients who took pasireotide LAR achieved greater disease control when it was compared with continued treatment with the standard somatostatin analogue therapies, octreotide LAR or lanreotide Autogel.

Acromegaly is a bad health condition which is caused by a benign (non-cancerous)tumor in the pituitary gland. This leads to secretion of excess growth hormone and can even cause enlargement of body parts including hands, feet and facial features.

This can also cause serious morbidities such as cardiovascular, metabolic and respiratory diseases.

novartis

Study author Dr. Monica Gadelha, who is a professor at Federal University of Rio de Janeiro, said, “Historically, we have evaluated somatostatin analogues for the treatment of acromegaly by the decrease in either growth hormone or insulin-like growth factor levels. With more sensitive assays and more stringent evaluation criteria, a recent meta-analysis indicates that up to 45 percent of patients can have either GH or IGF-I still elevated.”

“As the health risks associated with acromegaly may persist until both GH and IGF-1 levels are normalized, this study further supports the importance of monitoring for and achieving full biochemical control,” he further said.

Novartis study evaluated pasireotide LAR 40 mg and 60 mg against continued therapy with octreotide LAR or lanreotide Autogel. Only those patients were included in the study who did not achieve GH and IGF-1 biochemical control despite receiving the maximum approved doses of these currently available somatostatin analogues (SSAs).

During the trial period, researchers found that patients in significant number achieved biochemical control with each dose of pasireotide LAR compared to the octreotide LAR and lanreotide Autogel control arm.

 

Share this:

  • Tweet
  • Share on Tumblr
  • Email

Filed Under: Health Tagged With: acromegaly, LAR therapy, long-acting release, Novartis, Novartis drug, Signifor

Woman working out at the gym

Just 23% of Americans Are Working Out Enough in Their Spare Time

June 29, 2018 By Amelia Donovan

Poliovirus Therapy Gives Brain Cancer Patients New Hope (Study)

June 29, 2018 By Amelia Donovan

United Airlines airplane

Passenger Mysteriously Dies on United Airlines flight Bound for Boston

June 28, 2018 By Amelia Donovan

Breakfast sandwich

Here Are Some Foods No Nutritionist Would Ever Eat

June 27, 2018 By Amelia Donovan

Poppy flower

UN Warns of Surge in Opium-based Drugs and Cocaine Supply

June 27, 2018 By Amelia Donovan

U.S.-Canada border

French Jogger Detained 2 Weeks for Accidentally Crossing Border

June 26, 2018 By Amelia Donovan

Plus size model

Normalizing Plus Size Could Fuel Obesity Crisis (Study)

June 25, 2018 By Amelia Donovan

Giant manta ray

Unique Manta Ray Nursery Spotted off Texas Coast

June 23, 2018 By Amelia Donovan

The rainbow flag

WHO Scraps Transgenderism from List of Mental Illnesses

June 22, 2018 By Amelia Donovan

456 People Dead at U.K. Hospital after Taking too Many Painkillers

June 21, 2018 By Amelia Donovan

Kenyan girls dancing

Kenyans Facing Poor Nutrition as Supermarket Shopping Is on the Rise

June 20, 2018 By Amelia Donovan

Pages

  • About
  • Contact
  • Privacy Policy GDPR
  • Staff
  • Terms and Conditions

Recent Posts

  • Just 23% of Americans Are Working Out Enough in Their Spare Time
  • Poliovirus Therapy Gives Brain Cancer Patients New Hope (Study)
  • Passenger Mysteriously Dies on United Airlines flight Bound for Boston
  • Here Are Some Foods No Nutritionist Would Ever Eat
  • UN Warns of Surge in Opium-based Drugs and Cocaine Supply
  • French Jogger Detained 2 Weeks for Accidentally Crossing Border
  • Normalizing Plus Size Could Fuel Obesity Crisis (Study)

Related Articles

  • Woman working out at the gym

    Just 23% of Americans Are Working Out Enough in Their Spare Time

    Jun 29, 2018
  • Poliovirus Therapy Gives Brain Cancer Patients New Hope (Study)

    Jun 29, 2018
  • Breakfast sandwich

    Here Are Some Foods No Nutritionist Would Ever Eat

    Jun 27, 2018
  • Normalizing Plus Size Could Fuel Obesity Crisis (Study)

    Jun 25, 2018
  • The rainbow flag

    WHO Scraps Transgenderism from List of Mental Illnesses

    Jun 22, 2018
  • 456 People Dead at U.K. Hospital after Taking too Many Painkillers

    Jun 21, 2018
  • Young woman affected by depression

    If You Have PTSD You Were Likely Abused as a Child

    Jun 19, 2018
  • Obese dog on a leash

    Obese Dogs Can Help Us Better Understand How Obesity Works

    Jun 18, 2018
  • Our Brains Are Craving Combinations of Fats and Carbs (Study)

    Jun 15, 2018
  • Hungry bird with beck open

    Scientists Explain Why We Get ‘Hangry’

    Jun 13, 2018

Categories

  • Business
  • Entertainment
  • Health
  • National News
  • Nature
  • Provo
  • Salt Lake News
  • Science
  • Sports
  • State News
  • Tech & Science
  • Technology
  • Uncategorized
  • West Jordan
  • West Valley City
  • World

Copyright © 2021 utahpeoplespost.com

About · Privacy Policy · Terms of Use · Site Map · Contact

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This website uses cookies to ensure you get the best experience on our website. Learn more.